My trials
Accrual over time for My trials
Cumulative accrual
Accrual rate (patients per month)
Average since activation uses the ClinicalTrials.gov actual study start date. The recent rate uses up to the last 30 days of CTSU snapshots; a target date from it is projected only after 30 days.
Show accrual values as a table
Explore CTSU studies
Accrual pace
Fastest accruing (average since activation)
Data sources and methods
- Accrual comes from the public CTSU Protocol List (ctsu.cancer.gov/protocol), which lists active and temporarily closed NCI trials open to cross-group participation and reports actual over planned intervention accrual. These are study-wide totals across all sites, not accrual at any one institution.
- Status in the table is the CTSU protocol status when the trial is on the public protocol list. Open means Active, and the usual ClinicalTrials.gov pair is Recruiting. Temporarily Closed to Accrual, and Temporarily Closed to Accrual and Treatment, usually pair with Suspended. Approved, not yet open, is included from ClinicalTrials.gov as Not yet recruiting. Those trials are not on the public accrual feed, so they have no CTSU accrual number. An opened study shows the registry status. The status cell names that registry status when the pair is different. Closed to accrual, Complete, and Administratively complete are not on this list. Those usually appear on ClinicalTrials.gov as Active, not recruiting, Completed, or Terminated.
- History is built from one CTSU snapshot per day, starting . CTSU does not publish past accrual, so the line from the study start date to the first snapshot is a straight-line interpolation (dashed), not observed data.
- Average rate = current accrual divided by months since the actual study start date on ClinicalTrials.gov. Early ramp-up makes this lower than the current rate for most young trials. Recent rate = change over the last 30 days of snapshots, scaled to a month. Projected target date assumes the average rate continues.
- Accrual pace lists the fastest open studies that match the explorer filters, have been open at least 6 months, and have not reached their target. Patients per month favors large trials; % of target per month adjusts for trial size. The studies under that list start in protocol order. Column headings sort the table. On a phone, the same list is cards, with a Sort menu, and an opened study wraps to the screen.
- Site in the table is a short histology, 50 characters or fewer. A study with more than one histology, or a summary that would run past 50 characters, says Variety. The Site filter still rolls the CTSU disease list into the same oncology groups used on the WVU tracker. Leukemia, lymphoma, myeloma, myelofibrosis, and other hematopoietic neoplasms are Hematologic Cancer. Kidney, urothelial, and germ cell cancers are Genitourinary Cancers, and prostate studies are listed there as well as under Male Reproductive System Cancer. Bone, endocrine, and soft tissue stay their own sites. The opened study still shows the CTSU disease string. Disease burden is its own filter. Lead groups that start with LAO are one LAO filter choice. The protocol cell still shows the specific LAO code.
- Protocol brief on an opened study is a paraphrased summary of the current protocol on file: amendments, schema, and eligibility. The local tracker also shows pre-treatment assessments, assessments during treatment, assessments in follow-up, the study calendar, specimen collection, and data submission, including TRIAD when the protocol requires it. The public page leaves those out and points to the protocol on CTSU. A section is omitted when that protocol does not contain it. When no protocol is on file, the opened study says so instead of leaving the brief blank. It is not a copy of the protocol page. Confirm the current protocol before enrollment.
- Role starts with the three radiotherapy roles checked. RT-focused: RT named in the title. RT component: protocol-specified RT intervention, often part of the treatment backbone. Radiopharm: a therapeutic isotope (for example Lu-177 or Ac-225) without external-beam RT. Imaging tracers and MUGA scans are not radiopharmaceuticals. Studies outside those three roles are Imaging, Surgery, Transplant / cellular therapy, Cancer control, Registry / biospecimen, or Systemic therapy. Those boxes start unchecked. Manual overrides are listed in the evidence for each study.